ImmunityBio EU Approval Lifts Shares
ImmunityBio EU Approval expands ANKTIVA's approved footprint to 33 countries and sharpens trader focus on pricing, reimbursement, and trial-driven flow.
KEY TAKEAWAYS
- European Commission granted conditional marketing authorization for ANKTIVA across 33 countries.
- ImmunityBio reported FY25 revenue of approximately $113 million, a 700% year-over-year increase.
- Near-term focus on pricing and reimbursement to enable patient access and revenue growth.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
ImmunityBio said in a press release on Feb. 18, 2026, that the European Commission granted conditional marketing authorization for ANKTIVA with BCG to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). This approval expands the therapy’s footprint to 33 countries and sharpens near-term commercial catalysts.
EU Authorization and Market Expansion
The authorization covers 27 EU member states plus Iceland, Liechtenstein, and Norway, extending ANKTIVA’s approved markets across four regulatory jurisdictions: the EU+EEA, United States, United Kingdom, and Saudi Arabia. It is the first immunotherapy authorized in Europe for this indication, which regulators and the company highlight as significant for patients with limited treatment options. The European Commission requires ImmunityBio to submit long-term safety and efficacy data to the European Medicines Agency as a condition of approval. The authorization was secured in under two years following the product’s initial FDA clearance in April 2024.
Clinical Data and Commercial Outlook
ImmunityBio cited clinical trial results showing a 71% complete response rate, a median response duration of 26.6 months, and individual responses lasting beyond 54 months. The company reported fiscal 2025 revenue of approximately $113 million, a 700% year-over-year increase, reflecting a growing commercial base as it expands into new markets. Europe records more than 150,000 NMIBC diagnoses annually, with roughly 75% of bladder cancer cases classified as non-muscle invasive, underscoring the therapy’s addressable patient population.
Near-term priorities include securing pricing and reimbursement approvals across EU member states to enable patient access. The availability of six major BCG strains approved in Europe supports supply for the combination regimen, facilitating rollout plans. Upcoming trial readouts in bladder cancer and glioblastoma are key catalysts, with valuation sensitive to clinical setbacks. How quickly pricing, reimbursement, supply logistics, and trial results translate into patient access will determine whether the expanded approvals lead to sustained commercial growth.
